# Emilė Radytė

> Emilė Radytė is a Harvard- and Oxford-trained neuroscientist and the co-founder and CEO of Samphire Neuroscience, a London-based neurotech company building drug-free, hormone-free wearable devices for menstrual health. Her flagship product, Nettle, is a head-worn device using non-invasive transcranial direct current stimulation (tDCS) to target the neurological drivers of menstrual pain and mood symptoms. Named to the Forbes 30 Under 30 Healthcare list in 2024, she came up through emergency medicine at Harvard and a PhD in psychiatry and engineering at Oxford, and reframes conditions like PMS and PMDD as questions of brain circuitry rather than hormones alone.

- **Role:** Co-Founder & CEO at Samphire Neuroscience
- **Organizations:** Samphire Neuroscience, Integrative Neuroscience Association, NHS Innovation Accelerator, Harvard University, University of Oxford
- **From:** Lithuania
- **Nationality:** Lithuanian
- **Education:** BA in Neuroscience and Social Anthropology (summa cum laude); first graduate with a joint neuroscience-anthropology degree, Harvard University, MSc and PhD in Psychiatry and Engineering, specializing in non-invasive brain stimulation, University of Oxford
- **Known for:** Forbes 30 Under 30, Healthcare (2024), Developed Nettle, named 2024 Medical Innovation of the Year at Medica, Built a medically certified, drug-free and hormone-free therapeutic device for menstrual symptoms

## Career timeline

- **2016-2020** — Studied neuroscience and anthropology at Harvard; worked four years as an emergency medic and led Harvard's emergency medical service (90 medics)
- **2020** — Co-founded the Integrative Neuroscience Association, Lithuania's largest neuroscience NGO, during COVID-19 lockdown
- **2021** — Began MSc/PhD at Oxford in psychiatry and engineering, focused on non-invasive brain stimulation
- **2021** — Co-founded Samphire Neuroscience in London
- **2024** — Named to Forbes 30 Under 30 (Healthcare); Nettle wins Medical Innovation of the Year at Medica
- **2025** — Samphire raises ~$5M; company continues scaling its neurotech device for menstrual health

## Achievements

- Forbes 30 Under 30, Healthcare (2024)
- Developed Nettle, named 2024 Medical Innovation of the Year at Medica
- Built a medically certified, drug-free and hormone-free therapeutic device for menstrual symptoms
- First Harvard graduate to earn a joint degree in neuroscience and anthropology
- Led Harvard's emergency medical service of 90 medics
- Co-founded Lithuania's largest neuroscience NGO (400+ practitioners) and its first memory cafe for Alzheimer's patients
- NHS Innovation Accelerator Fellow
- Raised roughly $7.7M total funding for Samphire Neuroscience

## Latest updates

- **2025-06** — Samphire Neuroscience raised a funding round (Series A, ~$4.9M) to scale its menstrual-health neurotech device.
- **2024** — Named to Forbes 30 Under 30 Healthcare; Nettle recognized as Medical Innovation of the Year at Medica.

## Links

- Website: https://samphireneuro.com
- LinkedIn: http://www.linkedin.com/in/eradyte
- Facebook: https://www.facebook.com/samphireneuro/

---

Profile page: https://yespress.io/emile-radyte
Published by YesPress — https://yespress.io
Last updated: 2026-06-12